The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies
Li AW, Yin ES, Stahl M, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. Blood Reviews 2017, 31: 370-388. PMID: 28732587, DOI: 10.1016/j.blre.2017.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous manifestationsMyeloid malignanciesMyeloid diseasesCommon cutaneous manifestationStage of diseaseHematologists/oncologistsSignificant clinical implicationsMalignant hematopoietic cellsCutaneous involvementSkin manifestationsTargeted agentsSkin findingsClinical reviewCutaneous reactionsDermatologic findingsPrognostic valueImmune statusDiagnostic challengeEarly recognitionHematologic malignanciesMalignancyClinical implicationsDiseaseManifestationsHematopoietic cellsWell‐differentiated neuroendocrine tumors in skin: Terminology and diagnostic utility of cytokeratin 5/6 and p63
Panse G, Cowper SE, Leffell DJ, Pulitzer M, Ko CJ. Well‐differentiated neuroendocrine tumors in skin: Terminology and diagnostic utility of cytokeratin 5/6 and p63. Journal Of Cutaneous Pathology 2017, 44: 557-562. PMID: 28417484, DOI: 10.1111/cup.12952.Peer-Reviewed Original ResearchConceptsCutaneous adnexal neoplasmsAdnexal neoplasmsNeuroendocrine tumorsAdnexal tumorsBenign skin adnexal tumorCutaneous adnexal tumorsAggressive metastatic diseaseLow-grade tumorsSkin adnexal tumorsMajority of casesMetastatic diseaseMetastatic adenocarcinomaCarcinoid tumorsCytokeratin 5/6Diagnostic challengeDifferential diagnosisImmunohistochemical stainsCK5/6Diagnostic utilityPrimary siteTumorsNeoplasmsFirst signWDNETsP63